LCTX vs CBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Options & Structure while CBIO counters with relative strength in Momentum & Technical. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | CBIO Revenue | LCTX Op. Margin | CBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -837.9% | N/A | LCTX |
| FY2019 | $0M | N/A | -1106.0% | N/A | LCTX |
| FY2020 | $0M | $10M | -1448.4% | -506.8% | CBIO |
| FY2021 | $0M | $0M | -1133.6% | -5470.7% | LCTX |
| FY2022 | $10M | $0M | -153.2% | -63204.4% | LCTX |
| FY2023 | $10M | $0M | -276.5% | -392752.9% | LCTX |
| FY2024 | $10M | N/A | -226.1% | N/A | LCTX |
| FY2025 | $10M | $10M | -251.6% | -1407.5% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | CBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $207.4M | $539.5M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | +0.0% | Higher Growth | CBIO |
| Operating Margin (TTM) Profitability | -280.3% | -1228.4% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 16.2% | 0.0% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -160.8% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 0% ($1โ$2) | 23% ($9โ$27) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.39ฮฒ ยท 79% Vol | 1.18ฮฒ ยท 60% Vol | Lower Realized Risk | CBIO |
| Unified Institutional Score Composite Signal | 54.9 / 100 (HOLD) | 49.2 / 100 (HOLD) | Higher Composite | LCTX |